Sprycel

Chronic Myeloid Leukemia (CML)

Sprycel is used to treat adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the following situations:

• When the CML is in the chronic phase and has been newly diagnosed.
• When the CML is in the chronic, accelerated, or blast phase and other treatments did not work or caused side effects that could not be tolerated.

In children 1 year of age and older, Sprycel is used to treat Ph+ CML that is in the chronic phase.

Acute Lymphoblastic Leukemia (ALL)

Sprycel is used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia in:

• Adults who can no longer benefit from or cannot tolerate other therapies.
• Children 1 year of age and older with newly diagnosed Ph+ ALL, when used in combination with chemotherapy.

Mechanism of Action

Sprycel belongs to a class of medications called kinase inhibitors. It is designed to target and block the action of certain abnormal proteins that signal cancer cells to multiply uncontrollably.

Targeting Abnormal Proteins

In many cases of chronic myeloid leukemia (CML), a genetic change creates an abnormal protein called BCR-ABL. This protein acts like a switch that is stuck in the "on" position, constantly signaling the body to produce too many white blood cells. Sprycel works by:

• Binding to the BCR-ABL protein to block its signaling activity.
• Inhibiting other proteins, such as SRC family kinases, which are also involved in the growth of cancer cells.

Slowing Cancer Growth

By interfering with these specific signals, Sprycel helps to slow down or stop the production of cancerous cells. This targeted approach focuses on the molecular drivers of the disease, helping to manage the overproduction of abnormal blood cells in the body.

Common Side Effects

Many people taking Sprycel experience mild to moderate side effects. These may include:

• Diarrhea, nausea, or vomiting
• Headache and fatigue
• Muscle, bone, or joint pain
• Skin rash
• Fever and cough
• Mild swelling in the hands, ankles, or feet

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider if you experience:

• Fluid retention: Shortness of breath (especially when lying down), sudden weight gain, or swelling, which may indicate fluid buildup around the lungs, heart, or abdomen.
• Low blood cell counts: Signs of infection like fever and chills, or signs of bleeding such as unusual bruising, bloody stools, or nosebleeds.
• Heart rhythm problems: Dizziness, fainting, or a fast or irregular heartbeat.
• Pulmonary arterial hypertension: High blood pressure in the vessels that supply the lungs, which can cause shortness of breath and tiredness.
• Severe skin reactions: Skin pain followed by a red or purple rash that spreads and causes blistering or peeling.
• Liver problems: Loss of appetite, dark urine, or yellowing of the skin or eyes.

Myelosuppression

Treatment with Sprycel often causes a significant decrease in blood cell counts, including platelets (thrombocytopenia), white blood cells (neutropenia), and red blood cells (anemia). These conditions can increase the risk of bleeding and infection. Healthcare providers typically monitor complete blood counts weekly for the first two months of treatment and then periodically thereafter.

Bleeding and Hemorrhage

Serious and sometimes fatal bleeding can occur during treatment. This includes gastrointestinal bleeding and bleeding within the brain. The risk may be higher in patients who are also taking medications that inhibit platelet function or anticoagulants.

Fluid Retention

Sprycel is associated with fluid retention, which may lead to pleural effusion (fluid around the lungs), pericardial effusion (fluid around the heart), or pulmonary edema. Symptoms can include shortness of breath, a dry cough, or sudden weight gain. Severe cases may require medical intervention, such as drainage or a temporary interruption of the medication.

Cardiovascular Risks

• Pulmonary Arterial Hypertension (PAH): This medication can cause high blood pressure in the arteries of the lungs. This condition may be reversible if the drug is discontinued, but it requires ongoing monitoring for symptoms like fatigue and difficulty breathing.
• QT Prolongation: Sprycel may affect the electrical rhythm of the heart. This risk is higher in patients with low potassium or magnesium levels or those taking other medications that affect the heart rhythm.
• Heart Failure: Some patients may develop heart-related complications, including left ventricular dysfunction.

Tumor Lysis Syndrome

Rapid breakdown of cancer cells can lead to tumor lysis syndrome, a condition where high levels of certain chemicals enter the blood. This can cause kidney failure and heart rhythm problems. Patients with high tumor burdens or rapidly dividing cells are at higher risk.

Severe Skin Reactions

Cases of severe skin reactions, such as Stevens-Johnson syndrome and erythema multiforme, have been reported. Treatment may need to be permanently stopped if these reactions occur.

Pregnancy and Fetal Risk

Sprycel can cause fetal harm when administered to pregnant women. Effective contraception is recommended for females of reproductive potential during treatment and for 30 days after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment and for 30 days after the final dose.

Drug Interactions

Certain medications can significantly change the levels of Sprycel in the body. Strong CYP3A4 inhibitors can increase the risk of toxicity, while strong CYP3A4 inducers may reduce the drug's effectiveness. Additionally, medications that reduce stomach acid, such as proton pump inhibitors, H2 blockers, or antacids, can interfere with the absorption of Sprycel.

Pregnancy Considerations

Sprycel can cause harm to a developing fetus. Research indicates that the medication may lead to birth defects or other toxic effects on an embryo. Individuals who are pregnant or considering pregnancy should talk to their doctor about the risks associated with this medication.

To prevent pregnancy during treatment, the following precautions are generally advised:

• For females: Use effective contraception during treatment and for 30 days after the last dose.
• For males: Use effective contraception during treatment and for 30 days after the last dose if your partner can become pregnant.

Breastfeeding Considerations

It is currently unknown if the active ingredient in Sprycel passes into human breast milk. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended while taking this medication. It is advised to wait at least 2 weeks after the final dose before breastfeeding.

Available Forms

Sprycel is provided in two formulations for oral administration:

• Oral Tablets: These are film-coated tablets that are intended to be swallowed whole. They should not be crushed, chewed, or broken.
• Powder for Oral Suspension: This formulation is designed to be mixed with water to create a liquid suspension before use.

FDA Approval History

Sprycel was first approved by the U.S. Food and Drug Administration (FDA) in June 2006. Since its initial approval, its use has been expanded to include both adult and pediatric patients for various stages of leukemia.

Approved Indications

The FDA has approved Sprycel for the treatment of:

• Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
• Ph+ CML in chronic, accelerated, or myeloid/lymphoid blast phase in patients who are resistant or intolerant to other therapies, including imatinib.
• Ph+ acute lymphoblastic leukemia (ALL) in patients with resistance or intolerance to prior therapy.
• Pediatric patients (1 year and older) with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL in combination with chemotherapy.

Safety and Regulatory Monitoring

While Sprycel does not currently have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA has issued safety communications regarding its use. In 2011, the FDA notified the public that Sprycel may increase the risk of pulmonary arterial hypertension (PAH), a condition involving high blood pressure in the arteries of the lungs. Healthcare providers are advised to evaluate patients for signs and symptoms of PAH before and during treatment.

Insurance and Pharmacy Factors

The out-of-pocket cost for Sprycel is largely determined by your insurance plan's formulary and benefit design. Most plans cover the medication, but the amount you pay, such as a copay or coinsurance, can vary. Additionally, Sprycel is typically handled by specialty pharmacies rather than standard retail locations, which can affect how the drug is billed and delivered.

Generic Dasatinib

Generic versions of dasatinib are available. These versions contain the same active ingredient as Sprycel but are usually offered at a lower price point. Availability may depend on your specific pharmacy and insurance requirements.

Financial Assistance Programs

Financial support may be available for eligible patients through various channels:

• Manufacturer Coupons: Patients with commercial insurance may qualify for co-pay assistance programs that lower monthly costs.
• Patient Assistance Programs: These programs, often run by the manufacturer or non-profit organizations, provide medication at low or no cost to patients who meet specific income and insurance criteria.